<HTML>
<!-- Produced by edgar-services.com using EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2020 [PPXV9M0ULJ50VJXL0P8L]. www.edgarsuite.com -->
<HEAD>
<TITLE>UNITED STATES</TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><P align=center style='font:11.5pt Times New Roman;margin:0'>UNITED STATES<BR>SECURITIES AND EXCHANGE COMMISSION<BR>Washington, D.C. 20549</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:12pt Times New Roman;margin:0'><B>FORM 8-K</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0'><B>CURRENT REPORT</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0'><B>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B></P>
<P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0'>Date of Report (Date of earliest event reported): &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;September 30, 2020</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:9pt Times New Roman;margin:0'><FONT style='font-size:14pt;border-bottom:1px solid #000000'><B>VITRO DIAGNOSTICS, INC.</B></FONT><BR>(Exact Name of Registrant as Specified in its Charter)</P>
<P style='font:9pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse><TR><TD valign=top style=width:170.95pt><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>&#160;&#160;&#160;&#160;&#160;&#160;&#160;Nevada&#160;&#160;&#160;&#160;&#160;&#160;&#160;</FONT></P>
</TD><TD valign=top style=width:126.05pt><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>&#160;&#160;&#160;&#160;&#160;&#160;&#160;0-17378&#160;&#160;&#160;&#160;&#160;&#160;&#160;</FONT></P>
</TD><TD valign=top style=width:139.5pt><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>&#160;&#160;&#160;&#160;84-1012042&#160;&#160;&#160;&#160;</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:170.95pt><P style='font:9pt Times New Roman;margin:0'>(State or other jurisdiction<BR> of incorporation)</P>
</TD><TD valign=top style=width:126.05pt><P style='font:9pt Times New Roman;margin:0'>Commission File<BR>Number</P>
</TD><TD valign=top style=width:139.5pt><P style='font:9pt Times New Roman;margin:0'>(I.R.S. Employer Identification number)</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:9pt Times New Roman;margin:0'><FONT style='font-size:11pt;border-bottom:1px solid #000000'>4621 Technology Drive, Golden CO &nbsp;80403</FONT><BR>(Address of principal executive offices)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Zip Code)</P>
<P align=center style='font:8pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0'>Registrant's telephone number, including area code:&#160;&#160;&#160;<FONT style='border-bottom:1px solid #000000'>(303) 999-2130</FONT></P>
<P align=center style='font:9pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:9pt Times New Roman;margin:0'>______________________________________________________</P>
<P align=center style='font:9pt Times New Roman;margin:0'>(Former name or former address, if changed since last report)</P>
<P align=center style='font:9pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11.5pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:478.8pt><TR><TD valign=top style=width:41.4pt><P style='font:11.5pt Times New Roman;margin:0'>___</P>
</TD><TD valign=top style=width:437.4pt><P style='font:11.5pt Times New Roman;margin:0'>Written communications pursuant to Rule 425 under the Securities Act </P>
</TD></TR>
<TR><TD valign=top style=width:41.4pt><P style='font:11.5pt Times New Roman;margin:0'>___</P>
</TD><TD valign=top style=width:437.4pt><P style='font:11.5pt Times New Roman;margin:0'>Soliciting material pursuant to Rule 14a-12 under the Exchange Act</P>
</TD></TR>
<TR><TD valign=top style=width:41.4pt><P style='font:11.5pt Times New Roman;margin:0'>___</P>
</TD><TD valign=top style=width:437.4pt><P style='font:11.5pt Times New Roman;margin:0'>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act</P>
</TD></TR>
<TR><TD valign=top style=width:41.4pt><P style='font:11.5pt Times New Roman;margin:0'>___</P>
</TD><TD valign=top style=width:437.4pt><P style='font:11.5pt Times New Roman;margin:0'>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act</P>
</TD></TR>
</TABLE>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>Securities registered pursuant to Section 12(b) of the Act:</B></P>
<P style='font:10pt Times New Roman;margin:0'>&#160;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style='width:33.34%;border-bottom:1pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><B>Title of each Class</B></P>
</TD><TD valign=top style='width:33.34%;border-bottom:1pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><B>Trading Symbol</B></P>
</TD><TD valign=top style='width:33.34%;border-bottom:1pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><B>Name of each exchange on which registered</B></P>
</TD></TR>
<TR><TD valign=top><P align=center style='font:10pt Times New Roman;margin:0'>N/A</P>
</TD><TD valign=top><P align=center style='font:10pt Times New Roman;margin:0'>N/A</P>
</TD><TD valign=top><P align=center style='font:10pt Times New Roman;margin:0'>N/A</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11.5pt Times New Roman;margin-top:7.4pt;margin-bottom:0pt;margin-right:5.9pt'><FONT style=color:#231F20>Indicate by check mark whether the registrant is an emerging growth company as de&#64257;ned in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</FONT></P>
<P style='font:11.5pt Times New Roman;margin-top:0.5pt;margin-bottom:0pt'>&nbsp;</P>
<P style='font:11.5pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11.5pt Times New Roman;margin-left:36pt'><FONT style=color:#231F20>Emerging growth company</FONT></KBD><KBD style=margin-left:324pt></KBD><FONT style=color:#231F20>[ X ]</FONT>&nbsp;</P>
<P style='font:11.5pt Times New Roman;margin-top:0.15pt;margin-bottom:0pt'>&nbsp;</P>
<P style='font:11.5pt Times New Roman;margin-top:3.7pt;margin-bottom:0pt;margin-right:32.3pt'><FONT style=color:#231F20>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised &#64257;nancial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</FONT>&nbsp;&nbsp;<FONT style=color:#231F20>[ &nbsp;&nbsp;&nbsp;&nbsp;]</FONT></P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11.5pt Times New Roman;margin:0'><KBD style='position:absolute;font:11.5pt Times New Roman;margin-left:0pt'><FONT style='border-bottom:1px solid #000000'><B>ITEM </B><B>8.01</B></FONT></KBD><KBD style=margin-left:72pt></KBD><FONT style='border-bottom:1px solid #000000'><B>OTHER EVENTS</B></FONT>&nbsp;</P>
<P style='font:11.5pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11.5pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:12pt Times New Roman;margin-top:5pt;margin-bottom:5pt'>Effective September 30, 2020, &nbsp;the Securities and Exchange Commission (&#8220;Commission&#8221;) <FONT style=font-family:TimesNewRomanPSMT>announced the temporary suspension, pursuant to Section 12(k) of the Securities Exchange Act of 1934, of trading in the securities of Vitro Diagnostics, Inc. (&#8220;VODG&#8221;) (CIK No. 0000793171), of Golden, CO, commencing at 9:30 a.m. EDT on September 30, 2020, and terminating at 11:59 p.m. EDT on October 13, 2020. </FONT></P>
<P style='font:12pt TimesNewRomanPSMT;margin-top:5pt;margin-bottom:5pt'>The Commission temporarily suspended trading in the securities of VODG due to a lack of current and information about the company because it has not filed certain periodic reports with the Commission. </P>
<P style='font:12pt TimesNewRomanPSMT;margin-top:5pt;margin-bottom:5pt'>The Company has been in communication with the Commission regarding its delinquent filings and has developed a plan to regain compliance with the reporting requirements under Section 13(a) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). &nbsp;At the Company&#8217;s request, the Commission has referred the matter to the Division of Enforcement. &nbsp;The Company intends to request that the Commission undertake to deregister the Company&#8217;s common stock under Section 12(g) of the Exchange Act. &nbsp;That deregistration would then permit the Company to complete the audit of its financial statements for the two fiscal years ending October 31, 2019 and 2020 and file a new Form 10 registration statement under the Exchange Act to restore the Company to a current status. &nbsp;The Company hopes to be able to file the Form 10 in the first quarter of 2021 and qualify to trade on the OTC.QB.</P>
<P style='font:12pt Times New Roman;margin-top:5pt;margin-bottom:5pt'><FONT style=font-family:TimesNewRomanPSMT>The Company is grateful for the support of its stockholders and investors through this transition period.</FONT></P>
<P style='font:12pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:12pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11.5pt Times New Roman;margin-top:5pt;margin-bottom:5pt'>&nbsp;</P>
<P style='font:11.5pt Times New Roman;margin:0'><KBD style='position:absolute;font:11.5pt Times New Roman;margin-left:0pt'><FONT style='border-bottom:1px solid #000000'><B>ITEM 9.01</B></FONT><B>:</B></KBD><KBD style=margin-left:72pt></KBD><FONT style='border-bottom:1px solid #000000'><B>EXHIBITS</B></FONT>&nbsp;</P>
<P style='font:11.5pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:478.8pt><TR><TD valign=top style=width:36.9pt><P style='font:11.5pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:45pt><P style='font:11.5pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Item</FONT></P>
</TD><TD valign=top style=width:396.9pt><P style='font:11.5pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Title</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:36.9pt><P style='font:11.5pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:45pt><P style='font:11.5pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:396.9pt><P style='font:11.5pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:36.9pt><P style='font:11.5pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:45pt><P style='font:11.5pt Times New Roman;margin:0'>99.1</P>
</TD><TD valign=top style=width:396.9pt><P style='font:12pt Times New Roman;margin:0'><A href=vd_ex99z1.htm style=text-decoration:none><FONT style='color:#0563C1;border-bottom:1px solid #0563C1'>SEC Release No. 90048 dated September 29, 2020.</FONT></A></P>
</TD></TR>
</TABLE>
<P style='font:11.5pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:11.5pt Times New Roman;margin:0'><B>SIGNATURES</B></P>
<P style='font:11.5pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11.5pt Times New Roman;margin:0'>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>
<P style='font:11.5pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:32.4pt><P style='font:11.5pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:207pt><P style='font:11.5pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD colspan=2 valign=top style=width:239.4pt><P style='font:11.5pt Times New Roman;margin:0'><B>Vitro Diagnostics, Inc. </B><BR>(Registrant)</P>
</TD></TR>
<TR><TD valign=top style=width:32.4pt><P style='font:11.5pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:207pt><P style='font:11.5pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:13.5pt><P style='font:11.5pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:225.9pt><P style='font:11.5pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:10pt Times New Roman;margin:0'>2</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE style=border-collapse:collapse><TR style=height:27pt><TD valign=top style=width:32.4pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:207pt><P style='font:11.5pt Times New Roman;margin:0'>Dated: <FONT style='border-bottom:1px solid #000000'>October 1, 2020</FONT></P>
</TD><TD valign=top style=width:13.5pt><P style='font:11.5pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:225.9pt><P style='font:11.5pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'><I>/s/ James R. Musick</I></FONT><BR>James R. Musick, President and CEO</P>
</TD></TR>
<TR style=height:27pt><TD valign=top style=width:32.4pt><P style='font:11.5pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:207pt><P style='font:11.5pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:13.5pt><P style='font:11.5pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:225.9pt><P style='font:11.5pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:10pt Times New Roman;margin:0'>3</P>
</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "vd_8k.htm", "description": "CURRENT EVENT REPORT - FORM 8-K", "secsgml_size_bytes": 14759}]
{"company-data": {"conformed-name": "VITRO DIAGNOSTICS INC", "cik": "0000793171", "assigned-sic": "2836", "irs-number": "841012042", "state-of-incorporation": "NV", "fiscal-year-end": "1031"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-17378", "film-number": "201223016"}, "business-address": {"street1": "4621 TECHNOLOGY DRIVE", "city": "GOLDEN", "state": "CO", "zip": "80403", "phone": "(720) 859-4120"}, "mail-address": {"street1": "4621 TECHNOLOGY DRIVE", "city": "GOLDEN", "state": "CO", "zip": "80403"}, "former-company": [{"former-conformed-name": "LABTEK INC", "date-changed": "19870217"}, {"former-conformed-name": "IMPERIAL MANAGEMENT INC", "date-changed": "19870201"}]}
UNITED STATES
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):       September 30, 2020
VITRO DIAGNOSTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
Nevada
0-17378
84-1012042
(State or other jurisdiction
of incorporation)
Commission File
Number
(I.R.S. Employer Identification number)
4621 Technology Drive, Golden CO  80403
(Address of principal executive offices)                    (Zip Code)
Registrant's telephone number, including area code:
(303) 999-2130
______________________________________________________
(Former name or former address, if changed since last report)
___
Written communications pursuant to Rule 425 under the Securities Act
___
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
___
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
___
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class
Trading Symbol
Name of each exchange on which registered
N/A
N/A
N/A
Indicate by check mark whether the registrant is an emerging growth company as deﬁned in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
[ X ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised ﬁnancial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
[     ]
ITEM
8.01
OTHER EVENTS
Effective September 30, 2020,  the Securities and Exchange Commission ("Commission")
announced the temporary suspension, pursuant to Section 12(k) of the Securities Exchange Act of 1934, of trading in the securities of Vitro Diagnostics, Inc. ("VODG") (CIK No. 0000793171), of Golden, CO, commencing at 9:30 a.m. EDT on September 30, 2020, and terminating at 11:59 p.m. EDT on October 13, 2020.
The Commission temporarily suspended trading in the securities of VODG due to a lack of current and information about the company because it has not filed certain periodic reports with the Commission.
The Company has been in communication with the Commission regarding its delinquent filings and has developed a plan to regain compliance with the reporting requirements under Section 13(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act").  At the Company's request, the Commission has referred the matter to the Division of Enforcement.  The Company intends to request that the Commission undertake to deregister the Company's common stock under Section 12(g) of the Exchange Act.  That deregistration would then permit the Company to complete the audit of its financial statements for the two fiscal years ending October 31, 2019 and 2020 and file a new Form 10 registration statement under the Exchange Act to restore the Company to a current status.  The Company hopes to be able to file the Form 10 in the first quarter of 2021 and qualify to trade on the OTC.QB.
The Company is grateful for the support of its stockholders and investors through this transition period.
ITEM 9.01
:
EXHIBITS
Item
Title
99.1
SEC Release No. 90048 dated September 29, 2020.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Vitro Diagnostics, Inc.
(Registrant)
2
Dated:
October 1, 2020
/s/ James R. Musick
James R. Musick, President and CEO
3